Steven H. Holtzman, board member of Molecular Partners, is strategic advisor to Decibel Therapeutics where he served as president and chief executive officer until January 2020. Prior to joining Decibel in 2016, Mr. Holtzman served as executive vice president of corporate development at Biogen, Inc., where he created and led the program leadership and management group through six new drug approvals. He also led the business development and mergers and acquisitions group through successful completion of numerous transactions. Prior to Biogen, Mr. Holtzman served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology) and was a founder, member of the board and the executive vice president of DNX Corporation. Mr. Holtzman is a member of the board of directors of Visterra and Warp Drive Bio.
In the not-for-profit arena, Mr. Holtzman is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a presidential appointee to the U.S. National Bioethics Advisory Commission. Mr. Holtzman received his Bachelor of Arts in philosophy from Michigan State University and his Bachelor of Philosophy graduate degree from Corpus Christi College. He attended Oxford University as a Rhodes Scholar.